Details for New Drug Application (NDA): 206084
✉ Email this page to a colleague
NDA 206084 describes LYPQOZET, which is a drug marketed by Pharmobedient and is included in one NDA. Additional details are available on the LYPQOZET profile page.
The generic ingredient in LYPQOZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.
The generic ingredient in LYPQOZET is atorvastatin calcium; ezetimibe. There are sixty-two drug master file entries for this compound. Additional details are available on the atorvastatin calcium; ezetimibe profile page.
Summary for 206084
| Tradename: | LYPQOZET |
| Applicant: | Pharmobedient |
| Ingredient: | atorvastatin calcium; ezetimibe |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE;10MG | ||||
| Approval Date: | Apr 26, 2017 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 20MG BASE;10MG | ||||
| Approval Date: | Apr 26, 2017 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 40MG BASE;10MG | ||||
| Approval Date: | Apr 26, 2017 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
